Trandolapril: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Essential Hypertension

Drugs

Volumn 48, Issue 1, 1994, Pages 71-90

  Wiseman, Lynda R ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENZYME INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; NIFEDIPINE; PRODRUG; TRANDOLAPRIL; TRANDOLAPRILAT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOTENSION; LIVER METABOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; ORAL DRUG ADMINISTRATION; PRURITUS; RASH; REVIEW; VERTIGO;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CONTROLLED CLINICAL TRIALS; DRUG TOLERANCE; HUMANS; HYPERTENSION; INDOLES; MULTICENTER STUDIES;

EID: 0028275866     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199448010-00007     Document Type: Article

References (80)

1. Circulating versus local renin-angiotensin system in cardiovascular homeostasis
2. Converting enzyme inhibitors in the treatment of hypertension
3. Angiotensin-converting enzyme in rat brain and extraneural tissues visualized by quantitive autoradiography using 3H-trandolaprilate
4. Evidence that the prodrug trandolapril, a new ACE inhibitor, also displays a direct ACE inhibitory activity [abstract]
5. Potent tissue angiotensin converting enzyme (ACE) inhibition and prolonged hypotensive effect of trandolapril (RU44570) [abstract]
6. Angiotensin-converting enzyme inhibitors — cilazapril and other bicyclic hexahydropyridazines
7. Prolonged and tissue-selective inhibition of vascular angiotensin-converting enzyme by trandolapril: relevance to its antihypertensive action in spontaneously hypertensive rats
8. Compared effects of oral trandolapril and enalapril on tissue ACE activity in rats [abstract]
9. Differential effects of oral trandolapril and enalapril on rat tissue angiotensin-converting enzyme
10. Cardiovascular actions and tissue-converting enzyme inhibitory effects of chronic enalapril and trandolapril treatment of spontaneously hypertensive rats
11. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570)
12. Pharmacological action of a novel angiotensin converting enzyme (ACE) inhibitor, RU 44570, namely (−)-(2 S,3a R,7a S)-l-[(S)- N-(S)-1-ethoxycarbonyl-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid: in vivo ACE inhibiting effect and antihypertensive effect in various hypertensive models of rats [in Japanese]
13. Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers
14. Enhanced activation of renin during repeated administration of the converting enzyme inhibitor RU-44570 [abstract]
15. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition
16. Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor
17. Phase I study of the RU 44570, an angiotensin-converting enzyme inhibitor (I). Single dose administration/food interaction in healthy volunteers [in Japanese]
18. Pharmacokinetics and pharmacodynamics of a new once-daily ACE inhibitor trandolapril after repeated oral administration in patients with mild or moderate hypertension [abstract]
19. Acute effects of RU 44570 (trandolapril) on hemodynamic and endocrine responses during exercise in patients with essential hypertension [in Japanese]
20. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril
21. Antihypertensive effect of trandolapril administered once (OD) or twice daily (BID) on office and 24-hour ambulatory blood pressures [abstract]
22. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring
23. Durée d’action clinique du trandolapril chez l’hypertendu léger à modéré [abstract]
24. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril
25. Cardiac effects of trandolapril in hypertension
26. Efficacy of trandolapril in essential hypertension [abstract]
27. Effects of blood pressure reduction with trandolapril and enalapril on left ventricular hypertrophy and exercise tolerance
28. Converting enzyme inhibition: dissociation between antihypertensive and arterial effects
29. Long-term treatment with trandolapril opposes cardiac remodelling and prolongs survival after myocardial infarction in rats
30. Systemic and regional hemodynamic profile of five angiotensin I converting enzyme inhibitors in the spontaneously hypertensive rat
31. Disparate renal hemodynamic effects of trandolapril (T) and enalapril (E) in essential hypertensives (EH) [abstract]
32. Effect of RU 44570 (trandolapril) on renal function in patients with essential hypertension [in Japanese]
33. Effect of RU 44570 (trandolapril) on the blood pressure and serum lipids in patients with essential hypertension [in Japanese]
34. Influence of the non-sulfhydryl angiotensin-converting enzyme inhibitor trandolapril on lipid and carbohydrate metabolism related to exercise capacity in healthy subjects
35. Action of trandolapril on blood glucose control and microalbuminuria in hypertensive diabetics [in French]
36. Trandolapril
37. Pharmacokinetics and pharmacodynamics of 2mg trandolapril after repeated administration to patients with chronic renal failure and to healthy subjects [abstract]
38. Phase I study of the RU 44570, an angiotensin-converting enzyme inhibitor (III). Pharmacokinetics and pharmacodynamics study in healthy volunteers [in Japanese]
39. Phase I study of the RU 44570, an angiotensin-converting enzyme inhibitor (II). Multiple-dose administration in healthy volunteers [in Japanese]
40. Effect of food on the bioavailability of trandolapril and its active metabolite trandolaprilat after oral administration to healthy volunteers [abstract]
41. How do trandolapril, a new ACE inhibitor, and trandolaprilat, the major and active metabolite, bind to human blood constituents? [abstract]
42. Pharmacokinetics and pharmacodynamics of 2mg trandolapril after repeated administration in elderly patients with mild to moderate essential hypertension [abstract]
43. Pharmacokinetics of fosinopril in patients with various degrees of renal function
44. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency
45. Efficacy and safety of RU 44570 (trandolapril), a novel angiotensin enzyme inhibitor, in patients with essential hypertension — multicenter open pilot study [in Japanese]
46. Evaluation and quantification of the microcirculatory effects of trandolapril in hypertensives by laser-doppler flowmetry [abstract]
47. The effects of trandolapril on 24h ambulatory blood pressure in patients with mild to moderate essential hypertension [abstract]
48. Clinical evaluation of RU44570 (trandolapril), a novel angiotensin converting enzyme inhibitor, in patients with severe hypertension [in Japanese]
49. Once-daily trandolapril compared with the twice-daily formulation in the treatment of mild to moderate hypertension: assessment by conventional and ambulatory blood pressures
50. Placebo-controlled comparison of short-term efficacy and safety of 2, 4 and 8mg trandolapril in patients with mild to moderate hypertension — double-blind international mulitcentre trial [abstract]
51. Placebo controlled dose-ranging study of the efficacy and safety of 0.5, 1 and 2mg trandolapril in patients with mild to moderate hypertension — a double-blind multicentre international trial [abstract]
52. Clinical evaluation of angiotensin converting enzyme inhibitor, trandolapril (RU 44570) in patients with essential hypertension — multi-centred double-blind comparative study in comparison with enalaprilat maleate [in Japanese]
53. Double-blind comparison of efficacy and safety of trandolapril 4mg and enalapril 20mg in patients with mild to moderate hypertension [abstract]
54. Double-blind comparison of efficacy and safety of trandolapril 4mg and captopril 100mg in patients with mild to moderate essential hypertension [abstract]
55. Double-blind comparison of efficacy and safety of trandolapril 2mg and hydrochlorothiazide 25mg in patients with mild to moderate essential hypertension [abstract]
56. Effect of RU 44570 (trandolapril), a novel angiotensin converting enzyme inhibitor, in patients with essential hypertension — monotherapy and combination therapy with thiazides [in Japanese]
57. Clinical evaluation of RU 44570 (trandolapril), a novel angiotensin converting enzyme inhibitor, in the long-term treatment of patients with essential hypertension [in Japanese]
58. Double-blind comparison of efficacy and safety of trandolapril, nifedipine SR and their combination — a multicentre international trial [abstract]
59. Clinical experiences with trandolapril
60. Does trandolapril interact with warfarin? [abstract]
61. Pharmacokinetic interaction study between trandolapril, a new ACE inhibitor, and furosemide [abstract]
62. Is there a pharmacokinetic or pharmacodynamic interaction between trandolapril, a new ACE inhibitor and digoxin? [abstract]
63. Absence of interaction between trandolapril and nifedipine [abstract]
64. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors
65. Metabolic considerations in the choice of therapy for the patient with hypertension
66. Treatment selection considerations for the hypertensive diabetic patient